MoHAP, GSK Sign MoU to Enhance Therapeutic Innovations for Asthma & Chronic Obstructive Pulmonary Disease (COPD)

The Ministry of Health and Prevention, MoHAP, has recently signed a memorandum of understanding (MoU) with GlaxoSmithKline (GSK) to further enhance therapeutic innovations for asthma and chronic obstructive pulmonary disease (COPD) to improve the quality of life of patients and follow the correct methods of prevention, and to develop training programs for healthcare professionals at MoHAP’s hospitals and health care centers in accordance with the latest scientific developments.

Under this MoU, a “Virtual Pharmacy Academy” will be launched to help pharmacists understand the various conditions of respiratory diseases, through the provision of all educational materials and tools.

The academy will also form an accredited online platform for continuing medical education (CME) and for der developing a multi-disciplinary approach for the care and treatment of respiratory patients in the UAE, based on the general framework determined by the best international standards.

The agreement was signed at MoHAP premises by HE Dr. Youssif Al Serkal, Assistant Undersecretary for the Ministry’s Hospitals Sector, and Sameh El Fangary, General Manager, Gulf Cluster, GSK.

Enhancing Innovation in Healthcare Field

“The MoU comes as part of MoHAP’s vigorous efforts to enhance innovation in healthcare for respiratory patients, raise health awareness about asthma and COPD, and boost the capabilities of doctors and health care professionals, in terms of disease diagnosis, management, and treatment, within the context of developing outcomes of national indicators of respiratory and chronic diseases to achieve the objectives of the National Agenda 2021,” said HE Dr. Youssif Al Serkal.

Cooperation with International Companies

He added: “The agreement mainly focuses on encouraging innovation in providing health and therapeutic services of respiratory diseases. This includes organizing a series of scientific lectures for doctors and healthcare professionals on the latest developments of asthma and COPD.”

Our cooperation with the specialized global companies would help promote the healthcare quality, develop the health system, and bolster the constant rehabilitation of medical cadres, Al-Serkal concluded.

For his part, Sameh El Fangary said: “We are delighted to cooperate with MoHAP and share our local and international expertise to achieve our ultimate objective, which is improving the quality of life of patients. To that end, we are focusing on developing innovative medicines and providing them for the largest segment of patients.”

Through this agreement, we look forward to creating a future, in which asthma and COPD patients will be enjoying broader therapeutic options towards a healthy life, El Fangary concluded.

Email This Post